Results of HAPLO transplants in SAA
| Reference . | No. of patients . | Age, y . | Conditioning . | GVHD Proph . | SC source . | Engraftment . | GVHD 2-4 . | Alive at 1 y . |
|---|---|---|---|---|---|---|---|---|
| 36 | 26 | 30 | RIC | ATG CsA | BM | 92% | 10% | 84% |
| 37 | 21 | 14 | NMA | CD3 dep | PB | 96% | 30% | 94% |
| 38 | 8 | 30 | NMA | PTCY, FK, MMF | GPregimen; B | 75% | ||
| 39 | 17 | 19 | NMA | ATG, Basilix, CsA | GBM + GPB | 90% | 25% | 65% |
| 40 | 26 | 30 | NMA | ATG, CsA, MTX, MMF | GBM+GPB | 92% | 12% | 84% |
| 41 | 77 | 8 | NMA | ATG, CsA, MTX, MMF + MSC | GBM+GPB | 92% | 12% | 93% |
| 42 | 13 | 30 | RIC | PTCY, FK, MMF | BM | 100% | 10% | 100% |
| 43 | 89 | 25 | RIC | ATG, CsA, MTX, MMF | GBM+GPB | 97% | 30% | 86% |
| Total | 277 | 27 | 92% | 12% | 85% |
| Reference . | No. of patients . | Age, y . | Conditioning . | GVHD Proph . | SC source . | Engraftment . | GVHD 2-4 . | Alive at 1 y . |
|---|---|---|---|---|---|---|---|---|
| 36 | 26 | 30 | RIC | ATG CsA | BM | 92% | 10% | 84% |
| 37 | 21 | 14 | NMA | CD3 dep | PB | 96% | 30% | 94% |
| 38 | 8 | 30 | NMA | PTCY, FK, MMF | GPregimen; B | 75% | ||
| 39 | 17 | 19 | NMA | ATG, Basilix, CsA | GBM + GPB | 90% | 25% | 65% |
| 40 | 26 | 30 | NMA | ATG, CsA, MTX, MMF | GBM+GPB | 92% | 12% | 84% |
| 41 | 77 | 8 | NMA | ATG, CsA, MTX, MMF + MSC | GBM+GPB | 92% | 12% | 93% |
| 42 | 13 | 30 | RIC | PTCY, FK, MMF | BM | 100% | 10% | 100% |
| 43 | 89 | 25 | RIC | ATG, CsA, MTX, MMF | GBM+GPB | 97% | 30% | 86% |
| Total | 277 | 27 | 92% | 12% | 85% |
BM, bone marrow; FK, tacrolimus; GVHD Proph, GVHD prophylaxis; MMF, mycophenolate; NMA, nonmyeloablative regimen; PB, peripheral blood; PTCY, high-dose posttransplant cyclophosphamide; RIC, reduced intensity conditioning regimen; SC source, stem cell source.